Rep. David Taylor Sells Off Shares of Eli Lilly and Company (NYSE:LLY)

Representative David Taylor (Republican-Ohio) recently sold shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on November 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Eli Lilly and Company stock on November 3rd. The trade occurred in the Representative’s “DAVID TAYLOR TRUST > SARDINIA READY MIX 401(K) – DAVE” account.

Representative David Taylor also recently made the following trade(s):

  • Sold $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 11/5/2026.
  • Sold $1,001 – $15,000 in shares of Procter & Gamble (NYSE:PG) on 11/5/2026.
  • Purchased $1,001 – $15,000 in shares of Broadcom (NASDAQ:AVGO) on 11/5/2026.
  • Purchased $1,001 – $15,000 in shares of Lam Research (NASDAQ:LRCX) on 11/5/2026.
  • Purchased $1,001 – $15,000 in shares of Eaton (NYSE:ETN) on 11/3/2026.
  • Sold $1,001 – $15,000 in shares of Kroger (NYSE:KR) on 11/3/2026.
  • Purchased $1,001 – $15,000 in shares of AT&T (NYSE:T) on 11/3/2026.
  • Purchased $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOGL) on 11/3/2026.
  • Sold $1,001 – $15,000 in shares of Visa (NYSE:V) on 11/3/2026.
  • Sold $1,001 – $15,000 in shares of Amgen (NASDAQ:AMGN) on 11/3/2026.

Eli Lilly and Company Trading Up 1.2%

Shares of LLY stock traded up $16.77 on Friday, reaching $1,444.05. The company had a trading volume of 2,080,606 shares, compared to its average volume of 3,003,279. The stock has a market cap of $1.36 trillion, a PE ratio of 46.87, a PEG ratio of 1.71 and a beta of 0.40. The company has a 50-day moving average of $1,242.25 and a 200-day moving average of $1,110.30. The company has a current ratio of 1.39, a quick ratio of 1.00 and a debt-to-equity ratio of 1.17. Eli Lilly and Company has a 12 month low of $850.51 and a 12 month high of $1,460.00.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last issued its quarterly earnings data on Thursday, October 29th. The company reported $7.48 EPS for the quarter, topping the consensus estimate of $5.71 by $1.77. The business had revenue of $24.40 billion for the quarter, compared to the consensus estimate of $22.58 billion. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The firm’s revenue was up 38.6% compared to the same quarter last year. During the same quarter last year, the business posted $7.02 EPS. On average, equities analysts forecast that Eli Lilly and Company will post 35.70 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 0.5%. The ex-dividend date is Friday, November 13th. Eli Lilly and Company’s payout ratio is presently 22.46%.

Institutional Trading of Eli Lilly and Company

Several institutional investors and hedge funds have recently modified their holdings of the business. Flputnam Investment Management Co. increased its stake in Eli Lilly and Company by 23.8% in the third quarter. Flputnam Investment Management Co. now owns 110,068 shares of the company’s stock valued at $127,357,000 after acquiring an additional 21,126 shares during the last quarter. Acorns Advisers LLC lifted its stake in Eli Lilly and Company by 7.9% during the third quarter. Acorns Advisers LLC now owns 2,757 shares of the company’s stock worth $3,190,000 after purchasing an additional 202 shares during the last quarter. Perennial Investment Advisors LLC lifted its stake in Eli Lilly and Company by 21.1% during the third quarter. Perennial Investment Advisors LLC now owns 3,959 shares of the company’s stock worth $4,581,000 after purchasing an additional 690 shares during the last quarter. Haverford Trust Co lifted its stake in Eli Lilly and Company by 0.3% during the third quarter. Haverford Trust Co now owns 166,426 shares of the company’s stock worth $192,568,000 after purchasing an additional 466 shares during the last quarter. Finally, Financial Advisors Network Inc. boosted its holdings in shares of Eli Lilly and Company by 15.9% in the 3rd quarter. Financial Advisors Network Inc. now owns 518 shares of the company’s stock worth $599,000 after purchasing an additional 71 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the business’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the completion of the sale, the executive vice president directly owned 4,137 shares of the company’s stock, valued at $5,802,225.24. The trade was a 54.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the business’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the sale, the executive vice president directly owned 54,147 shares of the company’s stock, valued at approximately $63,628,139.70. This trade represents a 10.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.14% of the stock is currently owned by corporate insiders.

Trending Headlines about Eli Lilly and Company

Here are a few of the latest headlines about LLY:

  • Positive Sentiment: Lilly broke ground on a $3.5 billion Pennsylvania manufacturing facility intended to make next-generation obesity medicines, including investigational retatrutide. The project supports the company’s broader production expansion, although the site is not expected to begin operations until 2031. Lilly announces Pennsylvania manufacturing facility
  • Neutral Sentiment: Lilly is advancing an early-stage ALS drug study, but investors are still waiting for clinical data, so the update does not yet establish whether the treatment will succeed. Eli Lilly advances early ALS drug study
  • Negative Sentiment: China Merchants Securities downgraded Lilly from “buy” to “hold,” providing a cautionary view amid the positive product and capacity news. China Merchants Securities stock recommendations

Wall Street Analysts Forecast Growth

LLY has been the subject of several recent analyst reports. Argus raised their target price on Eli Lilly and Company from $1,300.00 to $1,550.00 and gave the stock a “buy” rating in a research note on Friday, October 30th. Royal Bank Of Canada boosted their price target on Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company an “outperform” rating in a research note on Friday, October 30th. Jefferies Financial Group increased their price target on Eli Lilly and Company from $1,610.00 to $1,700.00 and gave the stock a “buy” rating in a report on Monday, November 9th. Morgan Stanley raised their price objective on shares of Eli Lilly and Company from $1,430.00 to $1,596.00 and gave the stock an “overweight” rating in a research report on Friday, October 30th. Finally, Wall Street Zen upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Saturday, October 31st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $1,416.64.

Read Our Latest Report on LLY

About Representative Taylor

David Taylor (Republican Party) is a member of the U.S. House, representing Ohio’s 2nd Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Taylor (Republican Party) ran for election to the U.S. House to represent Ohio’s 2nd Congressional District. He won in the general election on November 5, 2024.

David Taylor graduated from Amelia High School. Taylor earned degrees from Miami University (Ohio) and the University of Dayton School of Law. Taylor’s career experience includes working as an attorney and as a businessman at Sardinia Ready Mix, Inc.

Eli Lilly and Company Company Profile

(Get Free Report)

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

Featured Articles

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.